Market Overview

UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug

Related RNN
Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform
Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society

Burrill initiated coverage on Rexahn Pharmaceuticals (NYSE: RNN) with a Market Outperform rating and a $1 price target.

Burrill commented, "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance. … Rexahn's leading oncology drug, Archexin, is a first-in-class anti-sense drug targeting the Akt-1 gene, with an orphan designation for glioblastoma, pancreatic, stomach, ovarian, and renal cancers. Rexahn has completed a Phase 2a trial in pancreatic cancer, with promising survival data in a subset of evaluable patients."

Rexahn Pharmaceuticals closed at $0.29 on Thursday.

Latest Ratings for RNN

Mar 2015MLV & CoInitiates Coverage onBuy
Sep 2014Laidlaw & Co.Initiates Coverage onBuy
Mar 2014Brinson PatrickInitiates Coverage onOutperform

View More Analyst Ratings for RNN
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (RNN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters